Company / Operating Income
Voyager Therapeutics, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$122.0M
FY2025
5-year range
-$73.6M / $122.0M
FY2021-FY2025
Trend
+340.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income changed +340% YoY in FY2025, a notable deviation from the 9-year average annual change of -5%.
Based on SEC 10-K filings.
$122M in FY2025 with a 3-year CAGR of +64.6%.
Improved from -$74M to $122M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- +64.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +64.6%, indicating consistent growth.
- In FY2025, operating income increased 340.0% year-over-year.
- Lowest operating income in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.34 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $122.0M | +340.0% |
| FY2024 | -$50.8M | +30.9% |
| FY2023 | -$73.6M | -368.8% |
| FY2022 | $27.4M | +153.0% |
| FY2021 | -$51.7M | +43.3% |
| FY2020 | -$91.1M | -26.8% |
| FY2019 | -$71.9M | -74.0% |
| FY2018 | -$41.3M | -103.9% |
| FY2017 | -$20.3M | -41.0% |
| FY2016 | -$14.4M | -281.5% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026